Treprostinil for pulmonary hypertension in newborns
Part of Genetic & congenital, Lungs & breathing clinical trials.
This study collects information on how well a medicine called treprostinil works and how safe it is for newborn babies with pulmonary hypertension (high blood pressure in the lungs). It is for babies who have already received this treatment as part of their regular care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby received at least one dose of treprostinil (a medicine given through a vein or under the skin).
- Your baby was less than 44 weeks old (since conception) when they started treprostinil.
- Your baby had or was suspected of having pulmonary hypertension (high blood pressure in the lungs) at that time.
- You give permission for your baby to be in the study.
- Your baby is covered by French social security.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether breathing in magnesium sulfate and giving sildenafil can improve breathing and lung blood vessel pressure in newborns with persistent pulmonary hypertension. It may help newborns who are having trouble oxygenating despite being on a ventilator.
This trial tests a medicine called treprostinil in children with severe pulmonary arterial hypertension (high blood pressure in the lungs). The study aims to see if it is safe and tolerable for kids who need this kind of therapy.
This study looks at how well treprostinil, a medication given by injection, works for people with pulmonary hypertension. It aims to gather real-world data to understand treatment trends and outcomes.
This program provides access to an inhaled medication called treprostinil for people who have pulmonary hypertension (high blood pressure in the lungs) related to interstitial lung disease (a type of lung scarring). The treatment aims to improve symptoms and quality of life.
This study tests a drug called treprostinil to see if it is safe and effective for people with intermediate-risk pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. If you join, you may receive the study drug along with your usual PAH medications, which could help improve your symptoms and slow the disease.
This trial tests whether an inhaled medication called treprostinil (which helps open blood vessels in the lungs) can improve exercise ability in people who get high blood pressure in the lungs only during exercise. Participation involves taking the medication and doing exercise tests to see how well you do.
Hear when a new Persistent Pulmonary Hypertension of Newborn trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.